Novo Nordisk A/S (Denmark) and Eli Lilly and Company (US) are Leading Players in the GLP-1 Analogues Market
The global GLP-1 Analogue market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period. Growth in the GLP-1 Analogue market is mainly driven by factors such as the expanding clinical pipeline, the effectiveness of the GLP-1 drug class in the treatment of lifestyle diseases, including obesity and type 2 diabetes, and the growing demand for these products. However, the increasing off-label use of these drugs is expected to hinder the growth of this market in the coming years.
The market for GLP-1 Analogue class drugs is highly consolidated, with two major players controlling major shares of the market. Prominent players in the market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), AstraZeneca (UK), and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China) among others.
To know about the assumptions considered for the study download the pdf brochure
Novo Nordisk A/S (Denmark) is an established player in this market. The company contributes significantly to the GLP-1 Analogue market. The company has a strong product portfolio, robust brand recognition, and geographic presence with distribution channels across the globe. The company has a focused approach towards the development of antidiabetic therapeutic products. The major revenue-generating GLP-1 Analogue drugs include ozempic and wegovy. The strong manufacturing ecosystem of the company makes it the largest manufacturer of insulin and GLP-1 globally. The company also has a wide range of potential therapeutic products in the clinical pipeline. Novo Nordisk also focuses on developing oral forms of its existing GLP-1 drugs, like semaglutide, making it more convenient for patients.
Eli Lilly and Company (US) is another key player in the GLP-1 Analogues market. The company has a strong focus on expanding its research and development pipeline in all phases of clinical development. The company invested ~USD 9 billion in R&D in 2023. The company leverages business development activities to strengthen its market position in the GLP-1 Analogues market. The company has three commercialized GLP-1 Analogues class drugs: Mounjaro, Trulicity, and Zepbound. These drugs bring in high revenue for the company, with Trulicity and Mounjaro accounting for ~36% of the company’s revenue in 2023.
Sanofi (France) is also a well-established player in the GLP-1 Analogue market. The company has one commercialized GLP-1 analogue drug, Soliqua. The major strengths of the company are a strong geographical presence and a wide customer base. For instance, the company markets its GLP-1 analogue drug, Soliqua in more than 80 countries and is constantly acquiring regulatory approvals for its GLP-1 products across different geographies. For example, in January 2023, the company received approval for its GLP-1 Analogue drug Soliqua, in China for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet, exercise, and other oral antidiabetic drugs. Additionally, in December 2023, SOLIQUA received National Reimbursement Drug List (NRDL) status in China.
Related Reports:
GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
